FRANKLIN, Mass., Sept. 5 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONTD) announced today the appointment of Mr. Harry G.
Mitchell as its Chief Financial Officer, Treasurer and Vice President of
Finance. In this position, Mr. Mitchell will be responsible for Sontra's
accounting and financial operations, including input to Sontra's business
strategic planning.
Mr. Mitchell is a Certified Public Accountant and has been the interim
CFO of Sontra since June 12, 2006. Previously, Mr. Mitchell has been the
Chief Executive Officer and/or Chief Financial Officer for several medical
device and technology companies. Since 2004, Mr. Mitchell has served as
President and Chief Executive Officer of MedTech Advances, Inc., a
privately-held medical device company focusing in the Diabetes Industry,
and has provided financial and other consulting services to several other
corporations. From 1999 to 2004, Mr. Mitchell was Senior Vice President and
Chief Financial Officer of Boston Medical Technologies, Inc., a privately
held medical device and information technology company focusing in the
Diabetes Industry. From 1997 to 1998, Mr. Mitchell was Senior Vice
President, Chief Financial Officer and Treasurer of Focus Enhancements,
Inc., a public company in the video imaging technology business.
Thomas W. Davison, Sontra's Chief Executive Officer and President
stated, "We are pleased to have Harry Mitchell join us permanently as Chief
Financial Officer. Harry has already had a significant positive impact on
our company and has brought extensive insight into our strategic planning
as a result of his broad experience in finance and the medical device
industry. He is a seasoned executive with mature and emerging public
companies, and I am sure that he will make a substantial contribution to
our corporate goals."
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal
science and is developing a non-invasive, continuous transdermal glucose
monitor ("CTGM") for principal use in the Intensive Care Market. Through
its platform technology, the SonoPrep(R) Permeation System, combined with
technical competencies in transdermal drug formulation, analysis, delivery
systems and biosensors, the Company is creating a new paradigm in
transdermal drug delivery and diagnosis. The CTGM and other company
products are being developed for several billion dollar market
opportunities, all utilizing skin permeation, chemistry and biosensor
technology developed by the Company. In addition, the Company is developing
products for transdermal delivery of large molecule drugs and vaccines.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and uncertainties. The
factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market and sell
products based on its technology, including a continuous transdermal
glucose monitor for the hospital ICU market; the expected size of the
market for the continuous transdermal glucose monitor for the hospital ICU
market; the expected benefits and efficacy of the SonoPrep device in
connection with diagnostics, vaccine delivery, glucose monitoring and
transdermal science; the availability of substantial additional funding to
conduct research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-KSB for the year ended December 31,
2005, our most recent quarterly reports on Form 10-QSB, and our current
reports on Form 8-K. We do not undertake to update these forward-looking
statements made by us.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
Investor Relations Contact:
Harry G. Mitchell, CFO
508-530-0311
hmitchell@sontra.com
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Harry G. Mitchell, CFO of Sontra Medical
Corporation, +1-508-530-0311, hmitchell@sontra.com
|
